[ad_1]
As reported by the group of Denis Logunov, Dell ‘Gamaleya Moscow National Epidemiological Research Institute, the results, referring to two studies carried out between June 18 and August 3, show that 100% of the participants (healthy adults between 18 and 60 years old) developed antibodies against the SarsCov2 virus, without having serious side effects. Russian researchers have tested two types of vaccines that exploit two different adenoviruses, that is, one of the viruses that cause colds, modified to carry the gene for the Spike protein, which allows the coronavirus to enter human cells.
The most common side effects reported were injection site pain, fever, headache, weakness, muscle and joint pain, but in mild form. The positive result, notes the virologist. Carlo Maria Bolt, director of the Microbiology unit at Rome’s Bambino Gesù Hospital, “is that the results of the vaccine that until now had only been announced in the newspapers by Russian politicians have finally been published in a scientific journal.” Here the results obtained in the phase 1, which is used to assess the toxicity of the vaccine, and in the phase 2, which is used to find the correct dose.
Vaccines have been tested in a small number of healthy volunteers, young and almost all male. Even with these limitations, the data are reassuring and the vaccine looks promising – Perno continues – because it behaves like other vaccines in terms of toxicity and produces an immune response that seems to neutralize the virus. However, the ‘phase 3 data – Bolt concludes – that’s it Cwaves over thousands of people, which also serves to verify if who has been vaccinated or who has not been infected more. The data from this phase are essential, and it is also advisable to expand the case history of these first volunteers, observed only for 1.5 months. However, the road seems to have started well.
September 4, 2020 (change September 4, 2020 | 19:28)
© REPRODUCTION RESERVED
[ad_2]
